Cargando…

Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis

OBJECTIVE: To systematically review outcomes in patients with refractory overactive bladder (OAB) patients who underwent sacral neuromodulation therapy (SNM) therapy after unsuccessful onabotulinumtoxinA (BTX) therapy, and to compare outcomes with those who SNM as initial therapy. METHODS: A systema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Guang, Xu, Yong, Qu, Genyi, Zhang, Yulong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105106/ https://www.ncbi.nlm.nih.gov/pubmed/32226049 http://dx.doi.org/10.1371/journal.pone.0230355

Ejemplares similares

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty
por: El-Azab, Ahmed S., et al.
Publicado: (2013)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis
por: Lo, Chi-Wen, et al.
Publicado: (2020)

OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice
por: Hamid, Rizwan, et al.
Publicado: (2020)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

Editorial Comment: Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function
por: Riccetto, Cássio L. Z.
Publicado: (2020)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder
por: DiCarlo‐Meacham, Angela M., et al.
Publicado: (2022)

A Feasibility Study to Evaluate Changes in Urinary Metabolites after OnabotulinumtoxinA Injection for Refractory Overactive Bladder
por: Tellechea, Laura M., et al.
Publicado: (2022)

OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020)

Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation
por: Trinh, Hamilton, et al.
Publicado: (2019)

Sleep disturbance changes in women after treatment of refractory overactive bladder with sacral neuromodulation
por: Sanderson, Derrick J., et al.
Publicado: (2020)

Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome
por: Hsiao, Sheng-Mou, et al.
Publicado: (2016)

Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA
por: Ethans, KD, et al.
Publicado: (2014)

Retrospective Observational Study of Treatment Patterns and Efficacy of onabotulinumtoxinA Therapy in Patients with Refractory Overactive Bladder in Clinical Practice
por: Ko, Kwang Jin, et al.
Publicado: (2023)

Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients
por: Reekmans, Mathias, et al.
Publicado: (2021)

Sacral neuromodulation in overactive bladder: a review and current perspectives
por: Sukhu, Troy, et al.
Publicado: (2016)

OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012)

von Brunn's Nests and Follicular Cystitis Following Intradetrusor OnabotulinumtoxinA Injections for Overactive Bladder
por: Nekkanti, Silpa, et al.
Publicado: (2017)

Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome
por: Shabir, Habiba, et al.
Publicado: (2021)

Effects of Acute Sacral Neuromodulation at Different Pulse Widths on Bladder Overactivity in Pigs
por: Cong, Huiling, et al.
Publicado: (2019)

300 IU vs. 200 IU of OnabotulinumtoxinA for detrusor overactivity
por: Persu, Cristian
Publicado: (2014)

Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance
por: Poole, Ruth Louise, et al.
Publicado: (2021)

Effects of Acute Sacral Neuromodulation at Different Frequencies on Bladder Overactivity in Pigs
por: Li, Xing, et al.
Publicado: (2017)

Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy
por: Hoag, Nathan, et al.
Publicado: (2016)

OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review
por: Zhang, Rui, et al.
Publicado: (2015)

Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study
por: Kaaki, Bilal, et al.
Publicado: (2020)

A comparative study between sacral neuromodulation and intravesical botulinum toxin injection for patients with refractory overactive bladder
por: Al-Azzawi, Issam S., et al.
Publicado: (2020)

Intermediate-term results of a prospective, multicenter study on remote programming sacral neuromodulation for refractory overactive bladder
por: Zhang, Yaoguang, et al.
Publicado: (2021)

OnabotulinumtoxinA in the treatment of refractory chronic cluster headache
por: Lampl, Christian, et al.
Publicado: (2018)

The Effects of Age, Gender, and Postvoid Residual Volume on Catheterization Rates After Treatment with OnabotulinumtoxinA for Overactive Bladder
por: Dmochowski, Roger, et al.
Publicado: (2023)

Sacral neuromodulation for overactive bladder using the InterStim and BetterStim systems
por: Meng, Lingfeng, et al.
Publicado: (2022)

Trigonal-Sparing vs. Trigonal-Involved OnabotulinumtoxinA Injection for the Treatment of Overactive Bladder: A Systematic Review and Meta-Analysis
por: Cui, Yuanshan, et al.
Publicado: (2021)

Using electroacupuncture with optimized acupoint positioning to predict the efficacy of sacral neuromodulation of refractory overactive bladder: A case report
por: Shen, Jianwu, et al.
Publicado: (2019)

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection on Elderly Patients with Chronic Central Nervous System Lesions and Overactive Bladder
por: Jiang, Yuan-Hong, et al.
Publicado: (2014)

Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery
por: Liao, Chun-Hou, et al.
Publicado: (2016)

Efficacy and Safety of OnabotulinumtoxinA in Treating Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis
por: Zhou, Xin, et al.
Publicado: (2015)

Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials
por: Arruda, Raquel Martins, et al.
Publicado: (2018)

Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder
por: Hsiao, Sheng-Mou, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9kck5k40e39ia4all9c0hsgd9j